Utility of 18F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody

Journal of the Medical Association of Thailand

Volumn 94, Issue 10, 2011, Pages 1238-1244

  Kingpetch, Kanaungnit ^a   Pipatrattana, Ratchapong ^a   Tepmongkol, Supatporn ^a   Sirisalipoch, Sasiton ^a   Chaiwatanarat, Tawatchai ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

18F FDG PET CT; Antithyroglobulin antibody; Differentiated thyroid carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; ANTI THYROGLOBULIN; ANTI-THYROGLOBULIN; AUTOANTIBODY; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BONE SCINTISCANNING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LOCAL METASTASIS; LYMPH NODE METASTASIS; MALE; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR LOCALIZATION; WHOLE BODY SCINTISCANNING; ADENOCARCINOMA; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; THYROID TUMOR; THYROIDECTOMY; WHOLE BODY IMAGING;

ADENOCARCINOMA; ADULT; AUTOANTIBODIES; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 84855554586     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Schlumberger MJ. Diagnostic follow-up of welldifferentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999; 22: 3-7.
2. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of welldifferentiated thyroid cancer: current strategies and future directions. Thyroid 2000; 10: 767-78.
3. Herle AJ, Uller RP. Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas. J Clin Invest 1975; 56: 272-7.
4. Black EG, Cassoni A, Gimlette TM, Harmer CL, Maisey MN, Oates GD, et al. Serum thyroglobulin in thyroid cancer. Lancet 1981; 2: 443-5.
5. Mariotti S, Cupini C, Giani C, Lari R, Rolleri E, Falco A, et al. Evaluation of a solid-phase immunoradiometric assay (IRMA) for serum thyroglobulin: effect of anti-thyroglobulin autoantibody. Clin Chim Acta 1982; 123: 347-55.
6. Feldt-Rasmussen U, Schlumberger M. European interlaboratory comparison of serum thyroglobulin measurement. J Endocrinol Invest 1988; 11: 175-81.
7. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 1121-7.
8. Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 2002; 57: 215-21.
9. Gorges R, Maniecki M, Jentzen W, Sheu SN, Mann K, Bockisch A, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005; 153: 49-55.
10. 131I whole-body scan. J Nucl Med 1999; 40: 986-92.
11. 131I whole body scan: a single-center study of 108 patients. Ann Nucl Med 2006; 20: 547-52.
12. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007; 48: 221-6.
13. Hall NC, Kloos RT. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Arq Bras Endocrinol Metabol 2007; 51: 793-805.